SCHEMBL14736112

SCHEMBL14736112

CC(=O)NOS(=O)(=O)c1c(C)cc(C)cc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.54
LMNA P02545 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
F2 P00734 3/20 0.46
PRSS1 P07477 3/20 0.46
PRSS2 P07478 3/20 0.46
PRSS3 P35030 3/20 0.46
RAB9A P51151 1/20 0.43
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6121500 0.87 CA1 (0.48) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL29082277 0.86 MAPT (0.51) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL29144118 0.80 SMN1; SMN2 (0.46) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL20638623 0.79 CA1 (0.47) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL25047 0.79 NFKB1 (0.42) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL187718 0.79 MEN1 (0.42) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL23172334 0.78 L3MBTL1 (0.47) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL17004464 0.78 MAPT (0.44) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL24969530 0.77 CA1 (0.48) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL8695488 0.76 SMN1; SMN2 (0.39) MAPTLMNAMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024182778-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2024-09-06 WO disclosed
CN-115515956-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-25 CN disclosed
US-11932639-B2 Fused ring heteroaryl compounds as ALK4/5 inhibitors BISICHEM CO., LTD. (KR) 2024-03-19 US disclosed
US-11919915-B2 Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations AGIOS PHARMACEUTICALS, INC. (US) 2024-03-05 US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230365592-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2023-11-16 US disclosed
EP-3691639-B1 CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-11-15 EP disclosed
US-20230339980-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. (US) 2023-10-26 US disclosed
EP-3802539-B1 TETRAHYDRO-1H-PYRAZINO[2,1-A]ISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN LA ROCHE (CH) 2023-09-20 EP disclosed
US-8980888-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-03-17 US disclosed
US-8980889-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-03-17 US disclosed
US-20140378448-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-12-25 US disclosed
US-20140378447-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-12-25 US disclosed
EP-2477990-B1 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-08-20 EP disclosed
US-8772510-B2 PDE10 modulators HOFFMANN-LA ROCHE INC. (US) 2014-07-08 US disclosed
EP-2507238-B1 DIPHENYL-PYRAZOLOPYRIDINE COMPOUNDS, THEIR PREPARATION AND THEIR APPLICATION AS MODULATORS OF THE NUCLEAR RECEPTOR NOT SANOFI SA (FR) 2013-07-31 EP disclosed
EP-2477988-B1 Acetylenic derivatives of 5-phenyl-pyrazolopyridine, process for their preparation and therapeutic use thereof SANOFI SA (FR) 2013-07-17 EP disclosed
WO-2013034506-A1 PDE10 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-14 WO disclosed
US-20130059833-A1 PDE10 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11919915-B2 Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations PAH, KDM8, PHF8 MAPT 2359/4885LMNA 798/4885MEN1 3131/4885
US-20130059833-A1 PDE10 MODULATORS PDE10A, PDE5A, PDE2A MAPT 1196/4885LMNA 3812/4885MEN1 2291/4885
US-20230365592-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 MAPT 2359/4885LMNA 798/4885MEN1 3131/4885
US-11932639-B2 Fused ring heteroaryl compounds as ALK4/5 inhibitors ALK, FGFR4, ALKBH3 MAPT 255/4885LMNA 2576/4885MEN1 3527/4885
US-20140378447-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A MAPT 75/4885LMNA 3655/4885MEN1 4110/4885
US-20140378448-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A MAPT 75/4885LMNA 3655/4885MEN1 4110/4885
US-20230339980-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 MAPT 2359/4885LMNA 798/4885MEN1 3131/4885
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME MALT1, FKBP1B, FKBP1A MAPT 3951/4885LMNA 4221/4885MEN1 82/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP MAPT 2516/4885LMNA 1308/4885MEN1 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.